Income Statement
ARROWHEAD PHARMACEUTICALS, INC.
ARWR
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Sep 30, 2025 2025 FY | Sep 30, 2024 2024 FY | Sep 30, 2023 2023 FY | Sep 30, 2022 2022 FY | Sep 30, 2021 2021 FY | Sep 30, 2020 2020 FY | Sep 30, 2019 2019 FY | Sep 30, 2018 2018 FY | Sep 30, 2017 2017 FY | Sep 30, 2016 2016 FY | Sep 30, 2015 2015 FY | Sep 30, 2014 2014 FY | Sep 30, 2013 2013 FY | Sep 30, 2012 2012 FY | Sep 30, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
829.45 | 3.55 | 240.74 | 243.23 | 138.29 | 87.99 | 168.80 | 16.14 | 31.41 | 0.16 | 0.38 | 0.18 | 0.29 | 0.15 | 0.30 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
829.45 | 3.55 | 240.74 | 243.23 | 138.29 | 87.99 | 168.80 | 16.14 | 31.41 | 0.16 | 0.38 | 0.18 | 0.29 | 0.15 | 0.30 |
|
Operating Expenses
|
731.10 | 604.63 | 445.74 | 421.74 | 287.32 | 181.15 | 107.60 | 72.08 | 68.40 | 81.90 | 96.36 | 53.45 | 24.88 | 21.24 | 10.13 |
|
Research & Development
|
607.16 | 505.87 | 353.19 | 297.31 | 206.34 | 128.87 | 81.05 | 52.97 | 31.69 | 41.45 | 47.27 | 23.14 | 8.71 | 5.39 | 3.28 |
|
Selling, General & Administrative
|
123.94 | 98.76 | 92.55 | 124.43 | 80.98 | 52.28 | 26.56 | 19.11 | 6.84 | 9.94 | 7.93 | 5.89 | 3.49 | 6.44 | 3.82 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
98.35 | -601.08 | -205.00 | -178.51 | -149.04 | -93.16 | 61.19 | -55.94 | -37.00 | -81.74 | -95.97 | -53.28 | -24.59 | -21.09 | -9.83 |
|
Non-Operating Income
|
-46.81 | -11.38 | -1.49 | 5.80 | 8.19 | 8.61 | 6.96 | 1.49 | 2.62 | 0.02 | 4.04 | -5.44 | -7.11 | -1.02 | 1.05 |
|
Interest Income
|
37.30 | 22.72 | 15.30 | - | - | - | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
63.33 | 9.32 | 18.33 | - | - | - | - | - | - | - | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
5.26 | -1.75 | 1.54 | 0.77 | 2.07 | -0.58 | - | 0.01 | 1.31 | 0.06 | 0.42 | -0.08 | -0.64 | -0.24 | -0.16 |
|
Income Before Tax
|
51.53 | -612.46 | -206.49 | -172.71 | -140.85 | -84.55 | 68.15 | -54.45 | -34.38 | -81.72 | -91.94 | -58.72 | -31.70 | -22.11 | -8.79 |
|
Income Tax Expense
|
53.16 | -12.97 | -1.22 | 3.35 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | -0.09 | -0.56 | -0.98 | -5.66 |
|
Non-Controlling Interest
|
31.75 | -10.20 | -4.00 | -0.43 | - | - | - | - | - | - | - | -0.10 | -0.56 | -0.98 | -0.36 |
|
Net Income
|
-1.63 | -599.49 | -205.28 | -176.06 | -140.85 | -84.55 | 67.97 | -54.45 | -34.38 | -81.72 | -91.94 | -58.63 | -31.14 | -21.13 | -3.13 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Sep 30, 2025 2025 FY | Sep 30, 2024 2024 FY | Sep 30, 2023 2023 FY | Sep 30, 2022 2022 FY | Sep 30, 2021 2021 FY | Sep 30, 2020 2020 FY | Sep 30, 2019 2019 FY | Sep 30, 2018 2018 FY | Sep 30, 2017 2017 FY | Sep 30, 2016 2016 FY | Sep 30, 2015 2015 FY | Sep 30, 2014 2014 FY | Sep 30, 2013 2013 FY | Sep 30, 2012 2012 FY | Sep 30, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
122.27 | -582.49 | -192.51 | -168.09 | -140.77 | -87.22 | 65.63 | -51.24 | -32.31 | -78.48 | -93.64 | -51.93 | -22.84 | -19.34 | -9.56 |
|
Earnings Per Share (Basic)
|
-0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.72 | - | - | - | - | - | - | -1.90 | -0.44 |
|
Diluted EPS
|
-0.01 | -5.00 | 0.66 | -1.67 | -1.36 | -0.84 | 0.69 | - | - | - | - | - | - | - | -0.40 |
|
Weighted Average Shares
|
133.76 | 119.78 | 106.75 | 105.43 | 103.75 | 100.72 | 93.86 | - | - | - | - | - | - | 11.13 | 7.18 |
|
Diluted Weighted Avg Shares
|
133.76 | 119.78 | 106.75 | 105.43 | 103.75 | 100.72 | 98.61 | - | - | - | - | - | - | - | 7.83 |
|
Comprehensive Income
|
- | - | - | - | -140.94 | -84.14 | 67.60 | -54.51 | -34.35 | -81.58 | -92.08 | - | - | - | - |